IL136462A0 - Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases - Google Patents

Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Info

Publication number
IL136462A0
IL136462A0 IL13646298A IL13646298A IL136462A0 IL 136462 A0 IL136462 A0 IL 136462A0 IL 13646298 A IL13646298 A IL 13646298A IL 13646298 A IL13646298 A IL 13646298A IL 136462 A0 IL136462 A0 IL 136462A0
Authority
IL
Israel
Prior art keywords
combination
proliferative diseases
antineoplastic drugs
treating proliferative
benzocycloheptapyridine
Prior art date
Application number
IL13646298A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL136462(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL136462A0 publication Critical patent/IL136462A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13646298A 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases IL136462A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29
PCT/US1998/026224 WO1999032114A1 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Publications (1)

Publication Number Publication Date
IL136462A0 true IL136462A0 (en) 2001-06-14

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13646298A IL136462A0 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Country Status (25)

Country Link
EP (1) EP1041985B1 (cs)
JP (1) JP4502503B2 (cs)
KR (1) KR100700907B1 (cs)
CN (1) CN1129431C (cs)
AR (1) AR017440A1 (cs)
AT (1) ATE317697T1 (cs)
AU (1) AU756762B2 (cs)
BR (1) BR9814419A (cs)
CA (1) CA2315693C (cs)
CL (1) CL2007001889A1 (cs)
CO (1) CO5080764A1 (cs)
CZ (1) CZ298511B6 (cs)
DE (1) DE69833509T2 (cs)
DK (1) DK1041985T3 (cs)
ES (1) ES2255196T3 (cs)
HU (1) HUP0102473A3 (cs)
IL (1) IL136462A0 (cs)
MY (1) MY137303A (cs)
NO (1) NO326832B1 (cs)
NZ (1) NZ504928A (cs)
PE (1) PE20000042A1 (cs)
PT (1) PT1041985E (cs)
SK (1) SK285584B6 (cs)
TW (1) TW581763B (cs)
WO (1) WO1999032114A1 (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
AU1400401A (en) * 1999-11-09 2001-06-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
EP1261348A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
CA2397657A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations with platinum compounds
CA2397253A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
CA2397475A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2001239275A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064195A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
ES2318000T3 (es) * 2001-02-15 2009-05-01 Janssen Pharmaceutica Nv Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos.
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
WO1997005902A1 (fr) * 1995-08-09 1997-02-20 Banyu Pharmaceutical Co., Ltd. Composition medicinale
CZ292791B6 (cs) * 1995-12-22 2003-12-17 Schering Corporation Tricyklické amidy, které se používají pro inhibici G-proteinové funkce a k léčení proliferativních onemocnění
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
AU715604B2 (en) * 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000508661A (ja) * 1996-04-15 2000-07-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 放射線および化学療法に対する細胞の感作
WO1997038664A2 (en) * 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
EP0934270A1 (en) * 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
HUP0004326A3 (en) * 1997-02-18 2003-07-28 Canji Inc San Diego Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Also Published As

Publication number Publication date
MY137303A (en) 2009-01-30
KR100700907B1 (ko) 2007-03-29
TW581763B (en) 2004-04-01
NO20003229L (no) 2000-08-22
CO5080764A1 (es) 2001-09-25
DK1041985T3 (da) 2006-06-19
WO1999032114A1 (en) 1999-07-01
AR017440A1 (es) 2001-09-05
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
EP1041985B1 (en) 2006-02-15
DE69833509D1 (de) 2006-04-20
PE20000042A1 (es) 2000-02-17
NO20003229D0 (no) 2000-06-21
CN1284875A (zh) 2001-02-21
CZ298511B6 (cs) 2007-10-24
JP4502503B2 (ja) 2010-07-14
JP2001526224A (ja) 2001-12-18
AU1907299A (en) 1999-07-12
DE69833509T2 (de) 2006-10-26
CA2315693C (en) 2010-11-30
CL2007001889A1 (es) 2008-01-11
NZ504928A (en) 2004-12-24
SK285584B6 (sk) 2007-04-05
AU756762B2 (en) 2003-01-23
ATE317697T1 (de) 2006-03-15
CN1129431C (zh) 2003-12-03
NO326832B1 (no) 2009-02-23
PT1041985E (pt) 2006-07-31
HUP0102473A2 (hu) 2002-01-28
CZ20002236A3 (cs) 2001-04-11
KR20010033452A (ko) 2001-04-25
EP1041985A1 (en) 2000-10-11
ES2255196T3 (es) 2006-06-16
HUP0102473A3 (en) 2003-07-28
SK8982000A3 (en) 2001-04-09

Similar Documents

Publication Publication Date Title
AP9700939A0 (en) Compounds and methods for the treatment of cancer
ZA971937B (en) Combinations for treatment of proliferative diseases.
PL330814A1 (en) Compounds for and methods of delivering pharmaceutical preparations and their application
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
HUP0102473A3 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
GB9812056D0 (en) Pharmaceutical composition for treatment of ibd and rbd
EP1077704A4 (en) COMBINATION THERAPY FOR TREATING DEPRESSION
AP9801414A0 (en) Combination effective for the treatment of impotence
PL344331A1 (en) Combination therapy for treatment of refractory depression
IL135518A0 (en) Use of macrolides for the treatment of cancer and macular degeneration
ZA983602B (en) Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination
ZA989556B (en) Benzoxazine derivatives their preparation and their therapeutic application
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
HUP0001263A3 (en) Methods of therapeutic administration of anti-cd4ol compounds
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
IL128351A0 (en) Pharmaceutical composition for treating viral diseases
GB2344586B (en) Isoquinuclidine derivatives,method of manufacturing the same and therapeutic agents for hypercholesterolemia containing these compounds
SG65766A1 (en) Composition for preventing and treating gingival diseases
AU6126498A (en) Method for the treatment of drug addiction and homeopathic remedy
HK1033259A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
ZA984650B (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
GB9615710D0 (en) Pharmaceutical preparations for the treatment of sarcocystosis